Pleural Diseases  >>  Caprelsa (vandetanib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Caprelsa (vandetanib) / Sanofi
NCT00402896: Malignant Pleural Effusion With ZD6474

Terminated
2
28
US
ZD6474, Vascular Endothelial Growth Factor Receptor, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
M.D. Anderson Cancer Center, United States Department of Defense, AstraZeneca
Lung Cancer, Pleural Effusion
06/14
06/14

Download Options